MK-4334 / Merck (MSD) - LARVOL DELTA

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD (Yahoo Finance) - "Bionomics Limited...today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD....Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375), was recently presented at the Society for Chemical Industry (SCI) and Royal Society of Chemistry (RSC) 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13, 2023....MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Schizophrenia • Tauopathies And Synucleinopathies

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Biomarker • Trial completion • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) (clinicaltrials.gov) - P1 | N=38 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting

Biomarker • Enrollment closed • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) (clinicaltrials.gov) - P1; N=54; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.

Biomarker • Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Oct 2019 ➔ Feb 2020; Initiation date: May 2019 ➔ Sep 2019; Trial primary completion date: Oct 2019 ➔ Feb 2020

Clinical • Trial completion date • Trial initiation date • Trial primary completion date